MedTrace Logo

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

NCT06886126 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2025-09-30

No results posted yet for this study

Summary

It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HDM1005 injection in nondiabetic obese adults.

Conditions

Interventions

DRUG

HDM1005 injection or placebo

HDM1005 injection subcutaneous injection QW for 22weeks

Sponsors & Collaborators

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaoying Li, Doctor · Zhongshan Hospital, Shanghai, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-07
Primary Completion
2025-09-23
Completion
2025-11-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06886126 on ClinicalTrials.gov